Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics (LPTX)
:LPTX
Holding LPTX?
Track your performance easily
LPTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.68 - $4.79
Previous CloseN/A
Volume72.74K
Average Volume (3M)419.20K
Market Cap
$98.86M
Enterprise Value$43.46M
Total Cash (Recent Filing)$793.00K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Mar 24, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding38,317,898
10 Day Avg. Volume441,686
30 Day Avg. Volume419,196
Standard Deviation0.37
R-Squared0.00056
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.65
Forecast
1Y Price Target
$5.50Price Target Upside113.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Leap Therapeutics News
PremiumCompany Announcements
Leap Therapeutics Reports Q3 2024 Progress and Financials
Ownership Overview
6.24% Insiders
3.39% Mutual Funds
0.13% Other Institutional Investors
84.47% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LPTX FAQ
What was Leap Therapeutics’s price range in the past 12 months?
Leap Therapeutics lowest stock price was $1.68 and its highest was $4.79 in the past 12 months.
What is Leap Therapeutics’s market cap?
Leap Therapeutics’s market cap is $98.86M.
When is Leap Therapeutics’s upcoming earnings report date?
Leap Therapeutics’s upcoming earnings report date is Mar 24, 2025 which is in 65 days.
How were Leap Therapeutics’s earnings last quarter?
Leap Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.494 by $0.054.
Is Leap Therapeutics overvalued?
According to Wall Street analysts Leap Therapeutics’s price is currently Undervalued.
Does Leap Therapeutics pay dividends?
Leap Therapeutics does not currently pay dividends.
What is Leap Therapeutics’s EPS estimate?
Leap Therapeutics’s EPS estimate is -0.41.
How many shares outstanding does Leap Therapeutics have?
Leap Therapeutics has 38,317,898 shares outstanding.
What happened to Leap Therapeutics’s price movement after its last earnings report?
Leap Therapeutics reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.494. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of Leap Therapeutics?
Currently, no hedge funds are holding shares in LPTX
---
Leap Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (113.18% Upside)
$5.50 (113.18% Upside)
Blogger Sentiment
Bullish
LPTX Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $18.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.96%
12-Months-Change
Fundamentals
Return on Equity
-106.79%
Trailing 12-Months
Asset Growth
-21.67%
Trailing 12-Months
Company Description
Leap Therapeutics
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
---
LPTX Stock 12 Month Forecast
Average Price Target
$5.50
▲(113.18% Upside)
Technical Analysis
Adial Pharmaceuticals
―
Fennec Pharmaceuticals
―
Karyopharm Therapeutics
―
Kazia Therapeutics
―
Eloxx Pharmaceuticals
―
Best Analysts Covering LPTX
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
-8.19%
reiterated a buy rating 3 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -8.19% per trade.
---